Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review

Table 3 Number of patients included by trial type.

Cancer Type	Studies Included	Total Patients	Number of Cetuximab	Cetuximab with Pulmonary Reaction	Number of Controls	Controls with Pulmonary Reaction
	n	n	n	n	n	n
Colorectal	23	3731	2227	76 (3.4)	1367	35 (2.6)
Head-Neck	10	1749	1004	173 (17.2)	516	104 (20.2)
Lung	10	1664	980	189 (19.6) †	671	82 (12.2)
Hepatobiliary/Pancreatic	5	209	167	9 (5.4)	42	0 (0.0)
Breast/Ovarian	3	78	78	10 (12.8)	0	0 (0.0)
Cutaneous	1	2	2	2 (100)	0	0 (0.0)
TOTAL:	52	7433	4458	459 (10.3) †	2596	221 (8.5)

Patients were grouped into those who received cetuximab, either alone or in combination with other therapeutics, and controls (those who did not receive cetuximab). † p < 0.05 compared to control group. * One study contained patients with either Head-Neck or Non-small cell lung cancer and is displayed in both groups.

ISSN: 1756-9966